학술논문
MPN-379 Matching-Adjusted Indirect Comparison (MAIC) of Pelabresib (CPI-0610) in Combination With Ruxolitinib vs. JAK Inhibitor Monotherapy in Patients With Intermediate or High-Risk Myelofibrosis
Document Type
Article
Author
Source
In: Clinical Lymphoma, Myeloma and Leukemia , Proceedings of the Society of Hematologic Oncology 2022 Annual Meeting. (Clinical Lymphoma, Myeloma and Leukemia, October 2022, 22:S336)
Subject
Language
English
ISSN
21522669
21522650
21522650